GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genenta Science SPA (FRA:K5F) » Definitions » Common Stock

Genenta Science SPA (FRA:K5F) Common Stock : €68.46 Mil (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Genenta Science SPA Common Stock?

Genenta Science SPA's quarterly common stock increased from Dec. 2023 (€67.34 Mil) to Jun. 2024 (€67.85 Mil) and increased from Jun. 2024 (€67.85 Mil) to Dec. 2024 (€68.46 Mil).

Genenta Science SPA's annual common stock increased from Dec. 2022 (€66.60 Mil) to Dec. 2023 (€67.34 Mil) and increased from Dec. 2023 (€67.34 Mil) to Dec. 2024 (€68.46 Mil).


Genenta Science SPA Common Stock Historical Data

The historical data trend for Genenta Science SPA's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genenta Science SPA Common Stock Chart

Genenta Science SPA Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Common Stock
Get a 7-Day Free Trial 0.04 65.88 66.60 67.34 68.46

Genenta Science SPA Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 66.60 67.02 67.34 67.85 68.46

Genenta Science SPA Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.


Genenta Science SPA Business Description

Traded in Other Exchanges
Address
Via Olgettina No. 58, Milan, ITA, 20132
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain.

Genenta Science SPA Headlines

No Headlines